Abstract:The common driver genes om lung adenocarcinoma mainly include epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), Kirsten rat sarcoma virus oncogene homology (KRAS), and c-ros proto-oncogene 1 tyrosine kinase (ROS1). In recent years, with the deepening of research on molecular signaling pathways, targeted therapy based on molecular markers and molecular typing has made great progress, gradually changing the treatment model into precision therapy guided by diver genes. Although the effects of targeted therapy are significant, almost all patients develop resistance after 6 months to 1 year of treatment. Immunotherapy is currently another research hotspot. Although immunotherapy takes effect slowly, its effects are long-lasting, which can complement targeted therapy. The combination of the two is a promising approach for overcoming resistance in treatment.
